Received Aug 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | SC |
Inappropriate Route of Administration (Subcutaneously instead of Intramuscularly); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 51-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 05-AUG-2025, the patient received Shingrix (subcutaneous). On 05-AUG-2025, an unknown time after receiving Shingrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Inappropriate Route of Administration (Subcutaneously instead of Intramuscularly)). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 06-AUG-2025 The pharmacist reported that a patient was administered Shingrix subcutaneously instead of intramuscularly, which led to intramuscular formulation administered by other route. The pharmacist wants guidance on this situation. The Vaccine Administration Facility is the same as Primary Reporter